51 related articles for article (PubMed ID: 38441065)
1. Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy.
Groeneveld CS; Fontugne J; Cabel L; Bernard-Pierrot I; Radvanyi F; Allory Y; de Reyniès A
Eur J Cancer; 2021 May; 148():181-189. PubMed ID: 33743486
[TBL] [Abstract][Full Text] [Related]
2. The Tumor Immune Landscape and Architecture of Tertiary Lymphoid Structures in Urothelial Cancer.
van Dijk N; Gil-Jimenez A; Silina K; van Montfoort ML; Einerhand S; Jonkman L; Voskuilen CS; Peters D; Sanders J; Lubeck Y; Broeks A; Hooijberg E; Vis DJ; van den Broek M; Wessels LFA; van Rhijn BWG; van der Heijden MS
Front Immunol; 2021; 12():793964. PubMed ID: 34987518
[TBL] [Abstract][Full Text] [Related]
3. A 12-chemokine gene signature is associated with the enhanced immunogram scores and is relevant for precision immunotherapy.
Li X; Wan Z; Liu X; Ou K; Yang L
Med Oncol; 2022 Jan; 39(4):43. PubMed ID: 35092511
[TBL] [Abstract][Full Text] [Related]
4. Can we yet use tertiary lymphoid structures as predictive biomarkers for immunotherapy response in melanoma?
Padonou F; Vanhulst T; Langouo-Fontsa MD
Curr Opin Oncol; 2024 Mar; 36(2):63-68. PubMed ID: 38441065
[TBL] [Abstract][Full Text] [Related]
5. Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation.
Salem D; Chelvanambi M; Storkus WJ; Fecek RJ
Front Immunol; 2021; 12():629519. PubMed ID: 33746966
[TBL] [Abstract][Full Text] [Related]
6. Tertiary Lymphoid Structures as a Predictive Biomarker of Response to Cancer Immunotherapies.
Trüb M; Zippelius A
Front Immunol; 2021; 12():674565. PubMed ID: 34054861
[TBL] [Abstract][Full Text] [Related]
7. [Tertiary lymphoid structures in cancer: From biology to therapeutic guides].
Quesada S; Lebreton C; Caux C; Italiano A; Dubois B
Bull Cancer; 2023 Jun; 110(6):657-664. PubMed ID: 37150731
[TBL] [Abstract][Full Text] [Related]
8. STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development.
Filderman JN; Appleman M; Chelvanambi M; Taylor JL; Storkus WJ
Front Immunol; 2021; 12():690105. PubMed ID: 34054879
[TBL] [Abstract][Full Text] [Related]
9. [Recent Progress of Tertiary Lymphoid Structure in Prognosis and Immunotherapy of Non-small Cell Lung Cancer].
Liu Y; Xiong L; Cai R; Chen Y; Ye J; Shen B; Zhou G
Zhongguo Fei Ai Za Zhi; 2023 Aug; 26(8):615-620. PubMed ID: 37752541
[TBL] [Abstract][Full Text] [Related]
10. Tertiary Lymphoid Structures and B cells: Clinical impact and therapeutic modulation in cancer.
Sautès-Fridman C; Verneau J; Sun CM; Moreira M; Chen TW; Meylan M; Petitprez F; Fridman WH
Semin Immunol; 2020 Apr; 48():101406. PubMed ID: 33248905
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
